11 October 2022 | Other

Merck's blood vessel disease drug passes final stage of testing

Merck & Co's $11.5 billion acquisition of pharmaceutical company Acceleron Pharma last year enabled Merck & Co to take advantage of therapy that achieved a major late-stage study goal in patients with advanced blood vessel disorder, Merck said on Monday.

Truist Securities analyst Robin Karnauskas said that in addition to the fact that the data obtained during testing confirm the correctness of the Acceleron deal, trial data also support Merck's promising cardiovascular drug line.

By 2030, Merck's cardiovascular product line is expected to consist of 8 approved drugs and reach a peak in sales of $10 billion, the company said.

Company MarketCheese
Period: 28.05.2026 Expectation: 155 pips
Investing in ETHUSD up to $2,425
Today at 11:11 AM 19
Gold buy
Period: 21.05.2026 Expectation: 900 pips
Purchasing gold with $4,790 in view during consolidation following recent correction
Today at 10:26 AM 17
Period: 14.07.2026 Expectation: 2700 pips
Investing in USDJPY with 160.700 target
Today at 09:21 AM 24
Period: 31.05.2026 Expectation: 900 pips
​​EURUSD sell-off targets 1.1655
Today at 09:12 AM 10
Period: 30.06.2026 Expectation: 1600 pips
Go short on SPX as correction risks mount
Today at 09:10 AM 7
Period: 21.05.2026 Expectation: 1500 pips
Selling S&P 500 with 7,300 target amid inflation shock and overheated market conditions
Today at 08:03 AM 14
Go to forecasts